Resection of single brain metastasis in non-small-cell lung cancer: Prognostic factors

被引:70
|
作者
Mussi, A
Pistolesi, M
Lucchi, M
Janni, A
Chella, A
Parenti, G
Rossi, G
Angeletti, CA
机构
[1] UNIV PISA, IST CLIN MED 2, I-56100 PISA, ITALY
[2] CNR, IST FISIOL CLIN, I-56100 PISA, ITALY
[3] UNIV PISA, IST NEUROCHIRURG, I-56100 PISA, ITALY
[4] CNR, IST FISIOL CLIN, REPARTO BIOSTAT & EPIDEMIOL, I-56100 PISA, ITALY
来源
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY | 1996年 / 112卷 / 01期
关键词
D O I
10.1016/S0022-5223(96)70190-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Combined resection of primary non-small-cell lung cancer and single brain metastasis is reportedly superior to other treatments in prolonging survival and disease-free interval. To identify prognostic factors that influenced survival we reviewed clinical records and follow-up data of 52 consecutive patients with non-small-cell lung cancer and single brain metastasis who had been evaluated for combined lung and brain operation: 19 had synchronous and 53 metachronous non-small-cell lung cancer and single brain metastasis, Seven patients were excluded from combined operation because of either early brain relapse after craniotomy or single brain metastasis localization in deep brain structures, Forty-one of the 45 patients who underwent combined operation had complete remission of neurologic symptoms. Actuarial 5-year survival from the second surgical intervention was 16% (median 19 months, range 1 to 104 months), N0 status and lobectomy were the only variables associated with longer survival. Actuarial 5-year survivals in patients with synchronous and metachronous presentation were 6.6% and 19%, respectively. In patients with metachronous presentation the length of survival was significantly associated with N0 status, lobectomy, and interval between lung and brain operation equal to or longer than 14.5 months. The subset of patients with N0 status and interval between operations longer than 14.5 months had a 61% 5-year survival. None of the patients with N1-2 disease and shorter interval between operations was alive at 20 months. These data indicate that prognostic factors may help to identify subsets of patients with markedly different outcomes after combined lung and brain operation.
引用
收藏
页码:146 / 153
页数:8
相关论文
共 50 条
  • [21] Spine Metastasis Is Associated with the Development of Brain Metastasis in Non-Small-Cell Lung Cancer Patients
    Cha, Hyung-Keun
    Ryu, Woo-Kyung
    Lee, Ha-Young
    Kim, Hyun-Jung
    Ryu, Jeong-Seon
    Lim, Jun-Hyeok
    MEDICINA-LITHUANIA, 2024, 60 (01):
  • [22] Brain Metastases of Non-Small Cell Lung Cancer: Prognostic Factors in Patients with Surgical Resection
    Ramos Antuna, Aida
    Alvarez Vega, Marco
    Rodriguez Sanchez, Carmen
    Martin Fernandez, Vanesa
    JOURNAL OF NEUROLOGICAL SURGERY PART A-CENTRAL EUROPEAN NEUROSURGERY, 2018, 79 (02) : 101 - 107
  • [23] Tumor markers as prognostic factors for non-small-cell lung cancer (NSCLC)
    Nestle, U
    Nieder, C
    Ukena, D
    Niewald, M
    Schnabel, K
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1257 - 1257
  • [24] PROGNOSTIC FACTORS IN STEREOTACTIC BODY RADIOTHERAPY FOR NON-SMALL-CELL LUNG CANCER
    Matsuo, Yukinori
    Shibuya, Keiko
    Nagata, Yasushi
    Takayama, Kenji
    Norihisa, Yoshiki
    Mizowaki, Takashi
    Narabayashi, Masaru
    Sakanaka, Katsuyuki
    Hiraoka, Masahiro
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (04): : 1104 - 1111
  • [25] A Multisite Study of Molecular Profiles of Brain Metastasis in Non-Small-Cell Lung Cancer
    Kokabee, M.
    Wuu, Y-R
    Vojnic, M.
    D'Amico, R. S.
    Wernicke, A. G.
    Harshan, M.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2023, 25 (06): : S51 - S52
  • [26] Pulsatile crizotinib treatment for brain metastasis in a patient with non-small-cell lung cancer
    Wang, S.
    Chen, J.
    Xie, Z.
    Xia, L.
    Luo, W.
    Li, J.
    Li, Q.
    Yang, Z.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2017, 42 (05) : 627 - 630
  • [27] Surgical treatment for gastrointestinal metastasis of non-small-cell lung cancer after pulmonary resection
    Fujiwara A.
    Okami J.
    Tokunaga T.
    Maeda J.
    Higashiyama M.
    Kodama K.
    General Thoracic and Cardiovascular Surgery, 2011, 59 (11) : 748 - 752
  • [28] Micrometastasis and skip metastasis as predictive factors in non-small-cell lung cancer staging
    Baisi, Alessandro
    Raveglia, Federico
    De Simone, Matilde
    Cioffi, Ugo
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2013, 43 (05) : 1075 - 1075
  • [29] Risk factors for brain metastases in patients with non-small-cell lung cancer
    An, Ning
    Jing, Wang
    Wang, Haoyi
    Li, Ji
    Liu, Yang
    Yu, Jinming
    Zhu, Hui
    CANCER MEDICINE, 2018, 7 (12): : 6357 - 6364
  • [30] Risk factors for bone metastasis in completely resected non-small-cell lung cancer
    Wang, Hui
    Zhang, Yan
    Zhu, Hui
    Yu, Jinming
    FUTURE ONCOLOGY, 2017, 13 (08) : 695 - 704